EUVIMEDEUVIMED entdecken
Crossref

Lipopolymeric Nanoplex-Mediated CRISPR/Cas9 Delivery for VEGF-A Knockdown in Psoriatic Angiogenesis

Abhay Tharmatt, Sonia Guha, Tushar Kumeria iD, Sushil Yadav, Anupama Mittal iD, Deepak Chitkara iD

ACS Applied Bio Materials · 2025

DOI: 10.1021/acsabm.5c01478 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Bio Materials, 2025. Verfasst von Abhay Tharmatt und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Birla Institute of Technology and Science Pilani, Vidya Vihar, Pilani, Rajasthan 333031, India. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Psoriasis, Vascular Endothelial Growth Factor A, Biocompatible Materials. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Birla Institute of Technology and Science, Pilani.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriasis is a chronic, incurable inflammatory skin disease characterized by immune cell infiltration, aberrant keratinocyte differentiation, and enhanced angiogenesis. Overexpression of the vascular endothelial growth factor-A (VEGF-A) gene promotes angiogenesis and is essential for endothelial cell migration, adhesion, and proliferation. Therefore, downregulating VEGF-A represents a promising therapeutic strategy for angiogenesis-related disorders. We investigated the application of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) ribonucleoprotein complexes (sgRNA/eGFP-Cas9 RNPs) targeting VEGF-A in psoriasis. To enable efficient delivery in vitro and in vivo, we developed lipopolymeric nanoplexes (NPXs) encapsulating sgRNA/eGFP-Cas9 RNPs. These NPXs exhibited a particle size of 142.2 nm (polydispersity index: 0.144), a zeta potential of +4.27 mV, and achieved >70% transfection efficiency in HaCaT (human immortalized keratinocyte) cells. Ex vivo skin permeation studies demonstrated 66% of permeation after 24 h. The optimized NPX formulation was incorporated into a Carbopol-based gel, which displayed non-Newtonian, shear-thinning behavior with variable thixotropy and achieved 48% of skin permeation after 24 h. In vivo efficacy assessment in an imiquimod-induced psoriasis model in Swiss albino mice showed significantly improved Psoriasis Area and Severity Index (PASI) scores, reduced epidermal damage, and suppressed keratinocyte proliferation compared to naked RNPs and blank gel controls. Gene editing analysis revealed an indel frequency of 40.7% by T7 endonuclease I assay and 14% by Sanger sequencing. Enhanced cellular uptake, efficient skin permeation and retention, and improved therapeutic efficacy collectively highlight the potential of NPX-mediated CRISPR/Cas9 delivery as a noninvasive strategy for psoriasis treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsPsoriasisVascular Endothelial Growth Factor ABiocompatible MaterialsNeovascularization, PathologicPolymersNanoparticlesHumansAnimalsParticle SizeMiceMaterials TestingGene Knockdown TechniquesAngiogenesis

Stichwörter der Autor:innen

CRISPR/Cas9VEGF-Aangiogenesisgene editingpsoriasisskin permeation

Substanzen

Vascular Endothelial Growth Factor ABiocompatible MaterialsPolymersVEGFA protein, human

Autor:innen und Institutionen

  • Department of Pharmacy, Birla Institute of Technology and Science Pilani, Vidya Vihar, Pilani, Rajasthan 333031, India.
  • School of Materials Science and Engineering, University of New South Wales, Sydney, New South Wales 2052, Australia.
  • Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, SAS Nagar, Punjab 160062, India.

ORCID-Profile: Tushar Kumeria, Anupama Mittal, Deepak Chitkara

Förderung

  • Birla Institute of Technology and Science, Pilani

Zitieren

APA

Tharmatt, A., Guha, S., Kumeria, T., Yadav, S., Mittal, A., & Chitkara, D. (2025). Lipopolymeric Nanoplex-Mediated CRISPR/Cas9 Delivery for VEGF-A Knockdown in Psoriatic Angiogenesis. ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.5c01478

Vancouver

Tharmatt A, Guha S, Kumeria T, Yadav S, Mittal A, Chitkara D. Lipopolymeric Nanoplex-Mediated CRISPR/Cas9 Delivery for VEGF-A Knockdown in Psoriatic Angiogenesis. ACS Applied Bio Materials. 2025. doi:10.1021/acsabm.5c01478

BibTeX
@article{Tharmatt2025,
  author = {Tharmatt, Abhay and Guha, Sonia and Kumeria, Tushar and Yadav, Sushil and Mittal, Anupama and Chitkara, Deepak},
  title = {Lipopolymeric Nanoplex-Mediated CRISPR/Cas9 Delivery for VEGF-A Knockdown in Psoriatic Angiogenesis},
  journal = {ACS Applied Bio Materials},
  year = {2025},
  doi = {10.1021/acsabm.5c01478}
}
Kostenlos starten →